0
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Predictors of Response to Carbamazepine Extended-Release Capsules Treatment in Bipolar Disorder

Pages 23-26 | Published online: 04 Dec 2011

References

  • Woods SW: The economic burden of bipolar disease. J Clin Psychi-atry 2000; 16\(suppl 13):38–41
  • Knoth RL, Chen K, Tafesse E: Datapoints: costs associated with the treatment of patients with bipolar disorder in a managed care orga-nization. Psychiatr Serv 2004; 55:1353
  • Gelenberg AJ, Pies R: Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry 2003; 15(3-4):203–216
  • Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ: Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16(2 suppl 1):24S–31S
  • Goldberg JF, Gam° IL, Leon AC, Kocsis III, Portera L: A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999; 60:733–740
  • Freeman TW, Clothier IL, Pazzaglia P. Lesem MD, Swann AC: A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108–111
  • Keck PE Jr, Nabulsi AA, Taylor IL, Henke CJ, Chmiel JJ, Stanton SP, Bennett JA: A pharmacoeconomic model of dival-proex vs. lithium in the acute and prophylactic treatment of bipo-lar I disorder. J Clin Psychiatry 1996; 57:213–222
  • Dilsaver SC, Swann AC, Shoaib AM, Bowers TC: The manic syndrome: factors which may predict a patient's response to lith-ium, carbamazepine and valproate. J Psychiatry Neurosci 1993; 18:61–66
  • Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21:71–83
  • Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM: Comparative prophylactic efficacy of lithium, car-bamazepine, and the combination in bipolar disorder. J Clin Psy-chiatry 1997; 58:470–478
  • Joffe RT, Post RM, Roy-Byrne PP, Uhde TW: Hematological effects of carbamazepine in patients with affective illness. Am J Psychiatry 1985; 142:1196–1199
  • Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group: A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:668–673

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.